Opin vísindi

Stability characterization, kinetics and mechanism of tacrolimus degradation in cyclodextrin solutions

Skoða venjulega færslu

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Prajapati, Manisha
dc.contributor.author Eiríksson, Finnur Freyr
dc.contributor.author Loftsson, Thorsteinn
dc.date.accessioned 2021-02-09T13:45:19Z
dc.date.available 2021-02-09T13:45:19Z
dc.date.issued 2020
dc.identifier.citation Prajapati, M., Eiriksson, F. F., & Loftsson, T. (2020). Stability characterization, kinetics and mechanism of tacrolimus degradation in cyclodextrin solutions. International Journal of Pharmaceutics, 586, 119579. doi:https://doi.org/10.1016/j.ijpharm.2020.119579
dc.identifier.issn 0378-5173
dc.identifier.uri https://hdl.handle.net/20.500.11815/2458
dc.description.abstract Tacrolimus is a macrolide lactone and potent immunosuppressant. It is highly lipophilic and has very limited aqueous solubility. Tacrolimus is highly susceptible to hydrolysis which results in very limited stability in aqueous solutions. Besides this, tacrolimus also undergoes dehydration and epimerization. Cyclodextrin (CD) complexation can increase the solubility and stability of hydrophobic drugs in aqueous solutions through the formation of drug/CD complexes. The aim of this study was to investigate degradation kinetics, mechanism and stability of tacrolimus in aqueous CD solutions, with the ultimate goal of developing an aqueous vehicle for ophthalmic delivery. For this, phase-solubility and kinetic studies in aqueous solutions containing different CDs at different pH values were performed. Mass spectrometry studies were also performed to elucidate the degradation mechanism of the drug in aqueous CD solution. The study showed that the drug has maximum stability between pH 4 and 6 and hydrolysis was the main cause of tacrolimus degradation in aqueous 2-hydroxypropyl-βCD (HPβCD) solutions. βCD and its derivatives were the better CD solubilizers for tacrolimus. The solubility and stability studies were further conducted with CD and surfactants, which is tyloxapol, tween 80 and poloxamer 407, where the combination provided better results compared to individual components.
dc.description.sponsorship This work was financially supported by the European Union grant no. MSCA-ITN-2017-765441 (transMed) and Faculty of Pharmaceutical Sciences, University of Iceland. Special thanks to Master students Ana Teresa Ferreira Nakov and Beatriz Maria Velez Alves for their help in the lab.
dc.language.iso en
dc.publisher Elsevier
dc.relation info:eu-repo/grantAgreement/EC/H2020/765441
dc.relation.ispartofseries International Journal of Pharmaceutics;Volume 586, 2020, 119579
dc.rights info:eu-repo/semantics/openAccess
dc.subject Cyclodextrins
dc.subject Tacrolimus
dc.subject Stability
dc.subject Solubility
dc.subject Kinetics
dc.subject Sýklódextrín
dc.subject Lyfjaefnafræði
dc.title Stability characterization, kinetics and mechanism of tacrolimus degradation in cyclodextrin solutions
dc.type info:eu-repo/semantics/article
dcterms.license Creative Commons Attribution 4.0 License
dc.identifier.journal International Journal of Pharmaceutics
dc.identifier.doi 10.1016/j.ijpharm.2020.119579
dc.contributor.department Lyfjafræðideild (HÍ)
dc.contributor.department Faculty of Pharmaceutical Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu